Digipath
CHM Cannabis
Home > Boards > US Listed > Biotechs >

Anavex Life Sciences Corp (AVXL)

AVXL RSS Feed
Add AVXL Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, Steady_T, blanka, 123tom, TomP1, Rubyred77
Search This Board: 
Last Post: 12/12/2018 11:55:46 PM - Followers: 719 - Board type: Free - Posts Today: 0

Anavex Life Sciences Corp (AVXL)



Company website:  http://www.anavex.com/
 
 Nasdaq 
 
Company Address:
51 West 52nd Street, 7th floor
New York, NY
10019 USA
1-844-689-3939

 
CIK:  0001314052
 

Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer.  The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.

Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease.  ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.  Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others.  The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial.  ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.

The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.

Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL

.
 
Management:   http://www.anavex.com/about-us/leadership/
 
Pipeline:  http://www.anavex.com/pipeline/

Patent Info: 
http://www.anavex.com/?s=patents

Clinical Trials:  https://clinicaltrials.gov/ct2/results?term=Anavex+Life+Sciences&Search=Search
 
Recent News:  http://finance.yahoo.com/q?s=avxl&ql=1
Company News Releases:  http://www.anavex.com/2015/?post_type=news
 
Filings:  http://www.sec.gov/cgi-bin/browse-edgar?company=anavex&owner=exclude&action=getcompany
 
Share Structure:  See SEC filings
 
Investor Relations:  ir@anavex.com

Marketing Details:  http://convention.bio.org/Printables/Anavex%20Life%20Sciences%20Corp..html

 



All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 
Digipath
CHM Cannabis
AVXL
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVXL News: Annual Report (10-k) 12/12/2018 04:42:54 PM
AVXL News: Anavex Life Sciences Reports Fiscal Year 2018 Financial Results And Provides Clinical Study Update 12/12/2018 07:00:00 AM
AVXL News: Anavex Life Sciences to Announce 2018 Fiscal Year End Financial Results on Wednesday, December 12, 2018 12/10/2018 07:00:00 AM
AVXL News: Anavex Life Sciences Strengthens its Scientific Advisory Board with Distinguished Researcher for Clinical Treatment of Parkin... 11/08/2018 07:00:00 AM
AVXL News: First Patient Enrolled in Anavex Life Sciences Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Dise... 10/30/2018 07:00:00 AM
News News Alert: Annual Report (10-k) 12/12/2018 04:42:54 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#173489  Sticky Note Compiled Due Diligence 12/2/18 XenaLives 12/02/18 01:47:50 PM
#166633  Sticky Note Thanks T... More to your post neiu 09/25/18 07:28:46 AM
#160507  Sticky Note here are a couple of those 32 from cninc 07/30/18 12:01:12 AM
#135567  Sticky Note Good lessons learned from AVXL investment in 2017. Rising_Sun 12/29/17 02:53:39 AM
#129044  Sticky Note People seem to always lose track of the dadofmarcmax 11/06/17 10:58:33 AM
#174271   The Phase 2 study commenced in October 2018 TTTav66 12/12/18 11:55:46 PM
#174270   We continue to identify and initiate discussions with Penny Double 12/12/18 11:04:17 PM
#174269   Are you forgetting this one? SMH! basparks79 12/12/18 10:51:22 PM
#174268   Blatantly and absolutely false: XenaLives 12/12/18 10:42:51 PM
#174267   In July 2018 the Company received approval from Penny Double 12/12/18 10:35:45 PM
#174266   Patent again - from 10-k This patent is combo Amatuer17 12/12/18 10:30:15 PM
#174265   10-k 371 phase 1 Penny Double 12/12/18 10:19:56 PM
#174264   Hey power... I was at the first basparks79 12/12/18 09:01:03 PM
#174263   Too see the efficiency ? Getting ahead for phase blanka 12/12/18 08:52:31 PM
#174262   With the three trials already being accounted for blanka 12/12/18 08:47:55 PM
#174261   Love the sentiment Tred, but reading this reminds dadofmarcmax 12/12/18 08:46:08 PM
#174260   The Phase 2a study met both primary and F1ash 12/12/18 08:40:45 PM
#174259   My personal preferred partnership scenario would be Eisai XenaLives 12/12/18 08:10:44 PM
#174258   Talon I agree and like the upbeat enthusiasm tredenwater2 12/12/18 08:05:20 PM
#174257   The net amount of other income for the F1ash 12/12/18 08:05:13 PM
#174255   Jon....Think CM has one or more potential partners Talon38 12/12/18 07:19:29 PM
#174254   Brad, Q1 CC (in February) will be interesting powerwalker 12/12/18 07:08:12 PM
#174253   Why the hush on the enrollment numbers? That Jonjones325 12/12/18 07:02:13 PM
#174252   Achievements like a two dollar stock? BIOChecker4 12/12/18 06:42:00 PM
#174251   I listened to the call as well and FitzyP33 12/12/18 06:01:13 PM
#174250   Would have liked a question regarding the pipeline. mauismart 12/12/18 06:00:31 PM
#174249   I listened to the conference call and I mauismart 12/12/18 05:47:58 PM
#174248   The FDA talks a good game but is Kentucky123 12/12/18 05:20:34 PM
#174247   "This was the best CC in the last plexrec 12/12/18 05:16:30 PM
#174246   Dr. M.'s heavy emphasis on AVXL Precision Medicine nidan7500 12/12/18 05:09:32 PM
#174245   I agree... based on Missling's responses to the basparks79 12/12/18 05:08:31 PM
#174243   Conf call a bit tame as usual: no Investor2014 12/12/18 05:05:51 PM
#174242   That was big news. The questions were Kentucky123 12/12/18 05:01:30 PM
#174241   I hope they give him a medal to ExtremelyBullishZig 12/12/18 04:56:02 PM
#174240   Sorry mr. Asperger's... He is on the mark ExtremelyBullishZig 12/12/18 04:54:04 PM
#174239   "2019 will be a year of execution" OFP 12/12/18 04:53:50 PM
#174238   Biggest news from the CC: The have Simonizer 12/12/18 04:53:44 PM
#174237   Dr Missling seems to be on target starting TomP1 12/12/18 04:47:32 PM
#174230   I've been on board for 3.5 years. poguemahone 12/12/18 04:25:26 PM
#174229   Any stock I've ever owned would be sold rayovacAAA 12/12/18 04:25:25 PM
#174227   tredenwater2BP partnership may come at the %50 enrollment nidan7500 12/12/18 04:17:39 PM
#174226   Tell that to Amarin AMRN McMagyar 12/12/18 04:15:55 PM
#174225   Jonjones325: Please stop asking questions that make sense. poguemahone 12/12/18 04:03:28 PM
#174223   Not correct: XenaLives 12/12/18 03:50:10 PM
#174222   Not correct: XenaLives 12/12/18 03:48:24 PM
#174221   I would like to hear what was said Kentucky123 12/12/18 03:37:15 PM
#174220   They only take questions from analysts... basparks79 12/12/18 03:30:54 PM
#174219   Conference Call at 4:30 pm est today. with biotechnician 12/12/18 03:29:02 PM
#174218   Nidan partnerships are typically built around milestones and tredenwater2 12/12/18 03:27:16 PM
#174216   The term should be "if the news hits. riaguy 12/12/18 03:09:55 PM
#174215   Keep on wishing Santa is coming. ?? sage4 12/12/18 03:07:54 PM
#174214   The cabal has been unsuccessful in shaking loose basparks79 12/12/18 02:56:10 PM
#174213   Running the same daily pattern as the past Kentucky123 12/12/18 02:46:23 PM
#174211   What is the reason for keeping the lid Jonjones325 12/12/18 02:43:56 PM
#174206   Re: "We need something to get us to basparks79 12/12/18 02:33:06 PM
PostSubject